Radiation Biology
Radiation therapy plays a role in the treatment of almost 60% of all cancer patients. Committed to advancing this important clinical tool, the scientists of the Radiation Biology Program collaborate across the laboratory and clinic to address the most critical questions in the field today.
Their cross-disciplinary efforts build on a history of innovation at Stanford that extends from the pioneering use of the linear accelerator in 1956 to treat retinoblastoma, a then-incurable eye cancer, to the development of the CyberKnife in 2002.
Today the program improves local tumor control and patient outcome through investigations into the tumor microenvironment. Combining their findings with advances in molecular imaging and radiation delivery techniques, program researchers are pursuing powerful new therapies that target tumors with unprecedented precision, as well as new methods for monitoring treatment delivery in real time.
Key areas of focus include:
- Complementary drugs to enhance radiotherapy
- New approaches to treatment delivery
- Genetic interventions for improved tumor control
Program Directors
Trial Administration